Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：6622） 兆科眼科的夥伴TENPOINT THERAPEUTICS, LTD. 接 獲FDA在美國 就BRIMOCHOL™ PF發出的批准 本 公 告 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 的 夥 伴Tenpoint Therapeutics, Ltd.（「Tenpoint」）已 接 獲 美 國 食 品 藥 品 監 督 管 理 局（「FDA」）批 准 商 業 化 卡 巴 膽 鹼 及 酒 石 酸 溴 莫 尼 丁 滴 眼 液（2.75%/0.1%）的 監 管 批 准。此 滴 眼 液 於 臨 床 試 驗 期 間 ...

Group 1 - The company has expanded its partnership with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™ PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL™ PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL™ PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint announced that the FDA has accepted the new drug application for BRIMOCHOL™ PF, with a review deadline set for January 28, 2026 [2] - The FDA has established a Prescription Drug User Fee Act (PDUFA) date for the drug, indicating progress towards commercialization [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL™PF in Vietnam [1] - AFT and Santen are the seventh and eighth commercialization partners for BRIMOCHOL™PF, indicating the company's commitment to global expansion [1] Group 2 - BRIMOCHOL™PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL™PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - The company has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL PF in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, marking them as the seventh and eighth commercialization partners for the product [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

（於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股份代號：6622） 兆科眼科有限公司 自 願 性 公 告－ 透過與AFT及 千 寿 建 立 夥 伴 關 係，推 動 用 於 治 療 老 花 眼 的 BRIMOCHOL™ PF於新加坡及越南的商業化進程 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本公司董事會欣然宣佈，本公司已擴大與領先健康護理產品製造商及分銷商AFT Pharmaceuticals Limited（「AFT」）的 夥 伴 協 議，以 於 新 加 坡 商 業 化BRIMOCHOL™ PF （「該產品」）。本 公 司 亦 已 與 亞 洲 領 先 眼 科 公 司 千 寿 製 薬 株 式 会 社（「千 寿」）建 立 策 略 夥 伴 關 係，以 於 越 南 商 業 化 該 產 品。 兆科分別授予AFT及 千 寿 於 新 加 坡 及 越 南 的 獨 家 分 銷 權，當 中 包 括 於 相 關 市 場 註 冊、進 口、推 廣、分 銷、營 銷 及 銷 售BRIMOCHOL™ PF的 權 利。透 過 該 等 協 議， AFT及千寿成為BRIM ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited 關於老花眼 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 自 願 性 公 佈－就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF 與PT FERRON訂立分銷協議 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 與 領 先 印 度 尼 西 亞 製 藥 公 司PT Ferron Par Pharmaceuticals（「PT Ferron」）就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF（由Tenpoint Therapeutics, Ltd.（「Tenpoint」）授 出 許 可 權 的 創 新 藥，用 ...

Summary of LENZ Therapeutics FY Conference Call Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Industry**: Ophthalmology, specifically focusing on presbyopia treatment - **Recent Development**: Recently approved therapy for presbyopia, an age-related vision condition affecting near vision [1][2] Core Points and Arguments Product Differentiation - LENZ Therapeutics developed an ophthalmic drop using aceclidine, a previously marketed glaucoma product, to treat presbyopia non-invasively [4][3] - The product aims to create a pin-hole pupil effect, improving near vision for patients aged 45 and older [6][7] - The target product profile includes a once-daily application that provides rapid and long-lasting effects, with 93% of patients achieving at least 20/40 vision [10][12] Clinical Data - Phase 3 CLARITY trials showed: - 71% of patients achieved a three-line improvement in near vision within 30 minutes [12] - 95% of participants achieved at least two lines of near vision improvement [11] - 93% of patients reached 20/40 vision or better within an hour, with 70% maintaining this level after 10 hours [10][13] Market Opportunity - There are approximately 128 million presbyopia patients in the U.S., with a significant portion expressing interest in an ophthalmic drop solution [7][19] - The company targets specific segments, including contact lens wearers, LASIK patients, and active aging individuals, each exceeding 10 million potential users [20][21][22] Commercial Strategy - The commercial strategy consists of three pillars: 1. **Doctors to recommend**: An 88-person sales force targeting 13,000 doctors, with a focus on optometry [14][16] 2. **Consumers to request**: A direct-to-consumer (DTC) campaign launching in Q1 2026 [15][44] 3. **Seamless access**: Ensuring easy access to the product through e-pharmacy and retail channels [15] Pricing Strategy - The product is priced at $79 per month, aligning with competitor VUITY, which had a successful launch at the same price point [24][25] - A three-month pack is available for $198, offering a lower monthly cost [25] Lessons from Competitors - The company learned from VUITY's experience, which had a strong initial launch but failed to maintain momentum due to efficacy issues [27][28] - LENZ Therapeutics emphasizes the importance of delivering on the product's promise of immediate results to avoid consumer disappointment [28][29] Key Performance Indicators (KPIs) - Metrics to track post-launch include: - Number of doctors prescribing the product - Frequency of prescriptions (refill rates) - Consumer engagement through the vis.com website [36][50] Additional Insights - The company has received positive anecdotal feedback from both patients and doctors regarding the product's efficacy and ease of use [40][41] - The marketing campaign will feature a celebrity endorsement and target platforms like Facebook, Instagram, and YouTube [46][48] Conclusion LENZ Therapeutics is positioned to capture a significant share of the presbyopia treatment market with its innovative ophthalmic drop, backed by strong clinical data and a comprehensive commercial strategy. The focus on immediate efficacy and targeted marketing will be crucial for the product's success in a competitive landscape.

Summary of LENZ Therapeutics Conference Call Company Overview - LENZ Therapeutics is a commercial company that has developed a presbyopia eye drop called Viz, which has recently received FDA approval [2][3] - Presbyopia affects approximately 128 million people in the U.S. alone, making it a significant market opportunity [2] Product Details - Viz is designed to restore near vision for up to 10 hours, allowing users to regain their previous vision quality [4][3] - The product's mechanism of action (MOA) is distinct from competitors, particularly Vuity, which is noted for its different side effect profile [4][3] Launch and Market Strategy - The product was FDA approved on July 31, 2025, and LENZ is preparing for a market launch with samples expected as early as October 2025 [5][9] - The company aims to build confidence among eye care professionals (ECPs) during Q4 2025, targeting over $1 million in revenue for that quarter [9][10] - For 2026, revenue consensus is projected at approximately $43 million, increasing to $125 million in 2027 [9][10] Competitive Landscape - Vuity, a previous competitor, had a strong launch despite its ineffectiveness, capturing only a small fraction of the presbyopia market [16][17] - LENZ anticipates a different outcome due to the efficacy of Viz and plans to leverage sampling to encourage trial and adoption [34][17] Sales and Distribution - The product will be sold through both retail and e-pharmacy channels, with a focus on e-pharmacy to streamline the purchasing process [12][26] - Upscript has been selected as the e-pharmacy partner, specializing in self-pay products [26][27] Regulatory and Market Position - Viz is classified as a new chemical entity (NCE) in the U.S., with expectations for NCE status to be listed in the Orange Book soon [21][22] - The product is designed to be user-friendly, with a straightforward prescription process for doctors [23][24] Future Outlook - LENZ is exploring opportunities for future products in ophthalmology, leveraging the success of Viz as a cornerstone for a broader portfolio [52][53] - The company is well-capitalized and does not feel urgent to license products in other regions, focusing on establishing a strong U.S. market presence first [50][51] Key Metrics and Monitoring - Early metrics for success will include the number of ECPs writing prescriptions and the refill rate of the product [12][14] - The company plans to provide updates on launch progress during quarterly calls and other conferences [15][49] Conclusion - LENZ Therapeutics is positioned to capitalize on a significant market opportunity with its innovative presbyopia treatment, Viz, and is focused on building a strong foundation for future growth in the ophthalmology sector [54][52]

Group 1 - The company has received FDA approval for its product, VIZZ, a week ahead of schedule, indicating strong regulatory support and potential market readiness [1] - VIZZ is an eye drop designed to treat presbyopia, a common age-related vision issue that affects individuals typically starting at age 45 [2] - The company is optimistic about the launch plans and sees significant opportunities for growth in the presbyopia treatment market over the next few quarters [1]